CN113698412A - 一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 - Google Patents
一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 Download PDFInfo
- Publication number
- CN113698412A CN113698412A CN202111019558.0A CN202111019558A CN113698412A CN 113698412 A CN113698412 A CN 113698412A CN 202111019558 A CN202111019558 A CN 202111019558A CN 113698412 A CN113698412 A CN 113698412A
- Authority
- CN
- China
- Prior art keywords
- coumarin
- pyrrole
- formula
- alkyl
- pyrrole derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960000956 coumarin Drugs 0.000 title claims abstract description 35
- 235000001671 coumarin Nutrition 0.000 title claims abstract description 35
- 150000003233 pyrroles Chemical class 0.000 title claims abstract description 30
- 238000001308 synthesis method Methods 0.000 title claims abstract description 13
- -1 furan alcohol compounds Chemical class 0.000 claims abstract description 17
- 239000003054 catalyst Substances 0.000 claims abstract description 10
- AHZAKFLOHIRCDU-UHFFFAOYSA-N 4-aminochromen-2-one Chemical class C1=CC=CC2=C1OC(=O)C=C2N AHZAKFLOHIRCDU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 3
- 230000036436 anti-hiv Effects 0.000 claims abstract description 3
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 3
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 3
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 3
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 20
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 16
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- 230000002194 synthesizing effect Effects 0.000 claims description 9
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- ICGWWCLWBPLPDF-UHFFFAOYSA-N furan-2-ol Chemical class OC1=CC=CO1 ICGWWCLWBPLPDF-UHFFFAOYSA-N 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 6
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000011968 lewis acid catalyst Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims 1
- 238000006555 catalytic reaction Methods 0.000 abstract description 2
- 229910000510 noble metal Inorganic materials 0.000 abstract description 2
- 238000007036 catalytic synthesis reaction Methods 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 42
- 238000003786 synthesis reaction Methods 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 238000001816 cooling Methods 0.000 description 12
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 12
- ZWRLWJAFBLTMSQ-UHFFFAOYSA-N Docosa-7,10,14-triensaeure Natural products C1C(C)=C2CC(C)(C)CC2C(O)C2=COC=C21 ZWRLWJAFBLTMSQ-UHFFFAOYSA-N 0.000 description 9
- YKASHPSKFYVZRC-UHFFFAOYSA-M furan-2-ylmethyl(trimethyl)azanium;iodide Chemical compound [I-].C[N+](C)(C)CC1=CC=CO1 YKASHPSKFYVZRC-UHFFFAOYSA-M 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 4
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000008204 material by function Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YQBLQKZERMAVDO-UHFFFAOYSA-N 2-oxo-2-phenylacetaldehyde;hydrate Chemical compound O.O=CC(=O)C1=CC=CC=C1 YQBLQKZERMAVDO-UHFFFAOYSA-N 0.000 description 1
- CKCOPMSBJBNBCQ-UHFFFAOYSA-N 3-chlorochromen-2-one Chemical compound C1=CC=C2OC(=O)C(Cl)=CC2=C1 CKCOPMSBJBNBCQ-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- BOHONKNXXMHSHO-UHFFFAOYSA-N 4-anilinochromen-2-one Chemical compound C12=CC=CC=C2OC(=O)C=C1NC1=CC=CC=C1 BOHONKNXXMHSHO-UHFFFAOYSA-N 0.000 description 1
- RKEYJFRSDLEQIE-UHFFFAOYSA-N 4-chlorochromen-2-one Chemical compound C1=CC=CC2=C1OC(=O)C=C2Cl RKEYJFRSDLEQIE-UHFFFAOYSA-N 0.000 description 1
- HGGVUFIBPFFZNK-UHFFFAOYSA-N C=1C=CNC=1.C1=CC=C2OC(=O)C=CC2=C1 Chemical compound C=1C=CNC=1.C1=CC=C2OC(=O)C=CC2=C1 HGGVUFIBPFFZNK-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 241000497386 Silveira Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- BCDGQXUMWHRQCB-UHFFFAOYSA-N glycine methyl ketone Natural products CC(=O)CN BCDGQXUMWHRQCB-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007243 oxidative cyclization reaction Methods 0.000 description 1
- 238000005839 oxidative dehydrogenation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007867 post-reaction treatment Methods 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了一种香豆素并[4,3‑b]吡咯类衍生物及其合成方法,该合成方法的具体步骤为:以4‑氨基香豆素类化合物和呋喃醇类化合物为原料,加入有机溶剂和催化剂,催化合成得到如式(I)所示的香豆素并[4,3‑b]吡咯类衍生物。本发明制备方法无需贵金属催化,且对环境友好。本发明还公开了式(I)所示香豆素并[4,3‑b]吡咯类衍生物在制备抗菌、抗肿瘤、抗氧化、抗HIV或抗凝血药物中的应用。
Description
技术领域
本发明属于有机化合物合成领域,具体涉及一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用
背景技术
香豆素并[4,3-b]吡咯类衍生物是一类重要的有机化合物,是许多天然产物、药物分子的核心骨架,具有抗真菌、抗病毒、抗炎、抗肿瘤、抗HIV、抗凝血以及抗氧化等广泛的药理作用,这些药效作用部分归因于香豆素并吡咯的平面结构修饰。另外香豆素并[4,3-b]吡咯类衍生物也可以应用于荧光探针等功能材料领域,其中的吡咯环可作为有机合成中间体,便于进一步衍生化。因此,发展该类化合物合成方法研究,对于相关药物分子、天然产物和功能材料的合成与修饰等,具有重要的现实意义。
关于香豆素并[4,3-b]吡咯类衍生物的合成已有文献报道,主要方法如下:1)分子内氧化环化反应,制备4-氨基香豆素衍生物,利用其分子内CDC氧化去氢偶联环化得到产物,例如,Cheng,C.;Chen,W.W.;Xu,B.;Xu,M.H.*J.Org.Chem.2016,81,11501-11507;2)分子间串联环化反应,主要是从4-氯香豆素、4-羟基香豆素、4-氨基香豆素出发,使之与-氨基丙酮类化合物、炔丙胺类化合物、非末端炔、苯甲酰甲醛水合物等发生多步串联环化反应得到产物,具体参考文献:[1]Liao,Y.X.;Kuo,P.Y.;Yang,D.Y.*Tetrahedron Letters,2003,44,1599-1602;[2]Majumdar,K.C.*;Samanta,S.K.Tetrahedron Letters,2002,43,2119-2121;[3]Peng,S.Y.;Wang,L.;Huang,J.Y.;Sun,S.F.;Guo,H.B.;Wang,J.*Adv.Synth.Catal.2013,355,2550-2557;[4]Chen,Z.W.;Yang,X.F.;Su,W.K.*TetrahedronLetters,2015,56,2476-2479;[5]Padilha,G.;Iglesias,B.A.;Back,D.F.;Kaufman,T.S.*;Silveira,C.C.*ChemistrySelect.,2017,2,1297-1304;
上述报道的合成方法中,存在以下问题:需要使用昂贵的贵金属催化剂,例如钯、银等,且需要以质子酸为反应溶剂;反应原料不易获得,需要多步合成实现;反应底物适用性有限,反应收率不高;反应需要在高温下进行;反应时间过长,需要长达72小时;反应后处理相对复杂,对环境不友好。上述合成方法从成本和环保的角度考虑具有一定的局限性。更重要的是,这些方法难以直接在香豆素并[4,3-b]吡咯2-位引入3,3-二取代基-2-丙酮基。
发明内容
本发明的目的是提供一种香豆素并[4,3-b]吡咯类衍生物及其合成方法,提供了一种无需贵金属催化、对环境友好的香豆素并[4,3-b]吡咯类衍生物合成方法。
本发明提供了一种香豆素并[4,3-b]吡咯类衍生物,其结构如式(I)所示:
式(I)中,R1为氢、C1-C10烷基、卤素或C1-C10烷氧基;R2为芳基或C1-C10烷基;R3为芳基或C1-C10烷基;R4为芳基或C1-C10烷基。
本发明还提供一种香豆素并[4,3-b]吡咯类衍生物的合成方法,具体步骤为:以4-氨基香豆素类化合物和呋喃醇类化合物为原料,加入有机溶剂和催化剂,催化合成得到如式(I)所示的香豆素并[4,3-b]吡咯类衍生物;
其反应过程如式(II)所示:
式(II)中,R1为氢、C1-C10烷基、卤素或C1-C10烷氧基;R2为芳基或C1-C10烷基;R3为芳基或C1-C10烷基;R4为芳基或C1-C10烷基。
优选地,R1为甲基、氯、甲氧基;R2为4-氯苯基、4-甲基苯基、4-酯基苯基、4-氟苯基、4-甲氧基苯基、2-甲氧基苯基、3-甲氧基苯基、1-萘基、正丁基、环戊基;R3为苯基、4-氯苯基、4-甲氧基苯基、正丁基;R4为苯基、4-氯苯基、4-甲氧基苯基、正丁基。
优选地,所述催化剂选自ZnCl2、Zn(OTf)2、BiCl3、AlCl3和TFA中的一种或多种。
优选地,所述有机溶剂选自1,2-二氯乙烷、乙腈、甲苯和氯仿中的一种或多种。
优选地,所述4-氨基香豆素类化合物:呋喃醇类化合物:催化剂的摩尔比为1:(1-2):(0.1-0.5)。
优选地,所述反应的温度为50-120℃。
优选地,所述反应的时间为1-20h。
优选地,所述反应的时间为2-5h。
本发明还提供了一种香豆素并[4,3-b]吡咯类衍生物在制备抗菌、抗肿瘤、抗氧化、抗HIV或抗凝血药物中的应用。
在一个具体实施方案中,本发明制备方法中,在空气下,以4-氨基香豆素类化合物和呋喃醇类化合物为原料,以AlCl3为催化剂,以1,2-二氯乙烷(DCE)为溶剂,在80℃下合成得到式(I)所示的香豆素并[4,3-b]吡咯类衍生物,如以下反应式(III)所示:
其中,R1为氢、C1-C10烷基、卤素或C1-C10烷氧基;R2为芳基或C1-C10烷基;R3为芳基或C1-C10烷基;R4为芳基或C1-C10烷基。
其中,所述4-氨基香豆素类化合物:呋喃醇类化合物:AlCl3的摩尔比为1:1.2:0.3。
其中,所述反应的时间为2-5h。
本发明的有益效果是:本发明的一种香豆素并[4,3-b]吡咯类衍生物的结构中引入3,3-二取代基-2-丙酮基,便于进一步衍生化,合成荧光探针或配体。本发明的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,使用路易斯酸催化剂,廉价易得,反应原料合成简单,反应条件温和。香豆素并[4,3-b]吡咯类衍生物的收率优秀,反应底物普适性好,后处理简便,对环境友好。
具体实施方式
为了使本发明所解决的技术问题、技术方案及有益效果更加清楚明白,以下结合实施例,对本发明进行进一步的详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。在不背离发明构思的精神和范围下,本领域技术人员能够想到的变化和优点都被包括在本发明中,并且以所附的权利要求书为保护范围。实施本发明的过程、条件、试剂、实验方法等,除以下专门提及的内容之外,均为本领域的普遍知识和公知常识,本发明没有特别限制内容。
实施例1:
1-苯基-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IA)合成
空气下,向10毫升封管中,加入4-苯胺基香豆素0.3mmol、呋喃醇0.36mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IA),橙色固体,分离收率85%。MP 176-178℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.74(s,1H),5.00(s,1H),6.43(dd,J1=8.0Hz,J2=1.2Hz,1H),6.78(s,1H),6.54(t,J=7.6Hz,1H),7.03-7.05(m,4H),7.23-7.28(m,9H),7.36(dd,J1=8.4Hz,J2=0.8Hz,1H),7.51(t,J=8.0Hz,2H),7.62(t,J=7.6Hz,1H);13C NMR(CDCl3,100MHz):δ40.34,63.21,108.08,109.90,113.95,117.74,120.56,123.41,127.35,128.22,128.75,130.12,130.18,132.80,135.65,137.02,137.60,152.07,158.99,203.36。
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C32H24NO3[M+H]+calc.:470.1751;found:470.1736。
实施例2:
1-苯基-2-(3,3-二苯基-2-丙酮基)-8-甲基香豆素并[4,3-b]吡咯(IB)合成
空气下,向10毫升封管中,加入6-甲基-4-苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IB),黄色固体,分离收率80%。MP 170-172℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ2.02(s,3H),3.74(s,2H),5.02(s,1H),6.14(s,1H),6.77(s,1H),7.03-7.07(m,5H),7.23-7.28(m,9H),7.50-7.53(m,2H),7.61-7.64(m,1H);13C NMR(CDCl3,100MHz):δ21.00,40.37,63.20,108.06,109.89,113.57,117.41,120.74,127.36,128.76,128.80,128.84,129.13,130.00,130.08,132.58,132.78,135.78,137.13,137.64,150.24,159.23,203.42。
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C33H26NO3[M+H]+calc.:484.1907;found:484.1895。
实施例3:
1-苯基-2-(3,3-二苯基-2-丙酮基)-7-甲氧基香豆素并[4,3-b]吡咯(IC)合成
空气下,向10毫升封管中,加入7-甲氧基-4-苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IC),黄色固体,分离收率75%。MP 189-192℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.71(s,2H),3.76(s,3H),5.00(s,1H),6.31(d,J=7.2Hz,1H),6.44(dd,J1=7.2Hz,J2=2.4Hz,1H),6.74(s,1H),6.87(d,J=2.4Hz,1H),7.03-7.05(m,4H),7.23-7.27(m,8H),7.48-7.51(m,2H),7.58-7.62(m,1H);13CNMR(CDCl3,100MHz):δ40.35,55.44,63.11,101.94,107.31,107.79,107.91,111.21,121.47,127.31,128.72,128.77,128.80,130.08,131.85,136.45,137.03,137.65,153.67,159.20,159.77,203.50。
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C33H26NO4[M+H]+calc.:500.1856;found:500.1848。
实施例4:
1-苯基-2-(3,3-二苯基-2-丙酮基)-8-氟香豆素并[4,3-b]吡咯(ID)合成
空气下,向10毫升封管中,加入6-氟-4-苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(ID),黄色固体,分离收率78%。MP 183-185℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.75(s,2H),5.00(s,1H),6.03(dd,J1=8.0Hz,J2=2.4Hz,1H),6.78(s,1H),6.94-6.98(m,1H),7.02-7.05(m,4H),7.23-7.29(m,8H),7.30-7.33(m,1H),7.52-7.55(m,2H),7.62-7.68(m,1H);13CNMR(CDCl3,100MHz):δ40.26,63.34,106.66(d,J=21.5Hz),108.23,110.34,114.58(d,J=7.7Hz),115.35(d,J=19.4Hz),119.03(d,J=7.0Hz),127.39,128.65,128.76,128.78,130.28,130.49,133.43,134.67,136.42,137.53,148.17(d,J=1.7Hz),157.04,158.65,158.96,203.25。
高分辨率质谱数据:HRMS(ESI,m/z)calcd.for C32H23FNO3[M+H]+calc.:488.1657;found:488.1646。
实施例5:
1-对甲苯基-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IE)合成
空气下,向10毫升封管中,加入4-对甲苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IE),淡黄色固体,分离收率75%。MP 182-183℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ2.52(s,3H),3.74(s,2H),5.01(s,1H),6.49(dd,J1=8.2Hz,J2=1.6Hz,1H),6.77(s,1H),6.85-6.89(m,1H),7.03-7.06(m,4H),7.11-7.13(m,2H),7.22-7.29(m,9H),7.36(dd,J1=8.4Hz,J2=1.2Hz,1H);13C NMR(CDCl3)δ:21.41,40.38,63.10,107.95,109.74,114.03,117.69,120.64,123.39,127.32,128.17,128.36,128.71,128.79,130.71,132.91,134.27,135.69,137.62,140.31,152.03,159.08,203.44。
HRMS(ESI,m/z)calcd.for C33H26NO3[M+H]+calc.:484.1907;found:484.1891。
实施例6:
1-对甲氧基苯基-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IF)合成
空气下,向10毫升封管中,加入4-对甲氧基苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IF),棕色固体,分离收率76%。MP 166-168℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.75(s,2H),3.93(s,3H),5.03(s,1H),6.52(dd,J1=8.0Hz,J2=2.4Hz,1H),6.76(s,1H),6.86-6.90(m,1H),6.95-6.97(m,2H),7.05-7.07(m,4H),7.15-7.17(m,2H),7.23-7.29(m,7H),7.36(dd,J1=8.4Hz,J2=1.2Hz,1H);13C NMR(CDCl3)δ:40.40,55.58,63.13,107.88,109.68,114.06,115.10,117.69,120.61,123.44,127.33,128.16,128.71,128.79,129.34,129.76,133.12,135.89,137.64,152.05,159.06,160.53,203.47。
HRMS(ESI,m/z)calcd.for C33H26NO4[M+H]+calc.:500.1856;found:500.1846。
实施例7:
1-(4-氟苯基)-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IG)合成
空气下,向10毫升封管中,加入4-对氟苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IG),b白色固体,分离收率78%。MP 157-158℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.77(s,2H),5.05(s,1H),6.44(dd,J1=8.0Hz,J2=1.6Hz,1H),6.76(s,1H),6.86-6.91(m,1H),7.05-7.08(m,4H),7.13-7.18(m,2H),7.24-7.31(m,9H),7.36(dd,J1=8.4Hz,J2=1.2Hz,1H);13CNMR(CDCl3)δ:40.34,63.11,108.21,109.95,113.80,117.14(d,J=22.6Hz),117.84,120.83,123.51,127.44,128.38,128.72,128.78,130.67(d,J=8.8Hz),132.78,132.86(d,J=3.4Hz),135.79,137.46,152.04,158.87,163.12(d,J=250.1Hz),203.41。
HRMS(ESI,m/z)calcd.for C32H23FNO3[M+H]+calc.:488.1657;found:488.1642。
实施例8:
1-对氯苯基-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IH)合成
空气下,向10毫升封管中,加入4-对氯苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IH),棕色固体,分离收率83%。MP 193-194℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.77(s,2H),5.04(s,1H),6.47(dd,J1=8.4Hz,J2=1.6Hz,1H),6.77(s,1H),6.88-6.92(m,1H),7.03-7.07(m,4H),7.19-7.23(m,2H),7.24-7.31(m,7H),7.36(dd,J1=8.4Hz,J2=1.2Hz,1H),7.42-7.45(m,2H);13C NMR(CDCl3)δ:40.32,63.17,108.42,110.10,113.76,117.88,120.37,123.56,127.47,128.44,128.73,128.81,130.14,130.35,132.65,135.47,135.69,136.32,137.44,152.07,158.83,203.35。
HRMS(ESI,m/z)calcd.for C32H23ClNO3[M+H]+calc.:504.1361;found:484.1340。
实施例9:
1-(4-乙氧甲酰基苯基)-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(II)合成
空气下,向10毫升封管中,加入4-对氯苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应3小时,然后冷却至室温,得到目标产物式(II),红棕色液体,分离收率82%。
产物核磁数据:1H NMR(CDCl3,400MHz):δ1.50(t,J=7.2Hz,3H),3.77(s,2H),4.50(q,J=6.8Hz,2H),5.03(s,1H),6.42(dd,J1=8.2Hz,J2=1.2Hz,1H),6.80(s,1H),7.03-7.06(m,1H),7.23-7.29(m,7H),7.34-7.38(m,3H),8.14-8.16(m,2H);13C NMR(CDCl3)δ:14.33,40.37,61.68,63.09,108.55,110.21,113.67,117.87,120.41,123.55,127.42,128.46,128.70,128.76,128.88,131.27,132.14,132.47,135.57,137.40,140.79,152.04,158.83,165.29,203.24。
HRMS(ESI,m/z)calcd.for C35H28NO5[M+H]+calc.:542.1962;found:542.1948。
实施例10:
1-(3-甲氧基苯基)-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IJ)合成
空气下,向10毫升封管中,加入3-甲氧基苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应3小时,然后冷却至室温,得到目标产物式(IJ),红棕色液体,分离收率85%。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.70(s,3H),3.76(dd,J1=18.6Hz,J2=14.0Hz,2H),5.00(s,1H),6.54(dd,J1=6.4Hz,J2=1.2Hz,1H),6.77(s,1H),6.79(t,J=2.0Hz,1H),6.85-6.89(m,2H),7.04-7.09(m,4H),7.14-7.16(m,1H),7.23-7.29(m,7H),7.36-7.43(m,2H);13C NMR(CDCl3)δ:40.44,55.52,63.22,108.10,109.83,113.67,113.91,116.68,117.72,120.65,120.70,123.51,127.33,127.39,128.27,128.71,128.73,128.80,130.79,132.78,135.60,137.59,137.69,137.99,152.06,159.04,160.69,203.52。
HRMS(ESI,m/z)calcd.for C33H26NO4[M+H]+calc.:500.1856;found:500.1834。
实施例11:
1-(3-氯苯基)-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IK)合成
空气下,向10毫升封管中,加入3-氯苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应2小时,然后冷却至室温,得到目标产物式(IK),淡棕色固体,分离收率82%。MP 77-80℃。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.76(s,2H),5.05(s,1H),6.46(dd,J1=6.4Hz,J2=1.2Hz,1H),6.78(s,1H),6.90(t,J=6.2Hz,1H),7.05-7.08(m,4H),7.18-7.20(m,1H),7.23-7.30(m,8H),7.38(dd,J1=6.6Hz,J2=1.2Hz,1H),7.43(t,J=6.4Hz,1H),7.59(dd,J1=6.4Hz,J2=2.4Hz,1H);13C NMR(CDCl3)δ:40.32,63.19,108.45,110.15,113.68,117.90,120.39,123.61,127.26,127.44,127.47,128.48,128.70,128.76,128.80,128.82,128.94,130.62,131.03,132.62,135.65,135.68,137.44,137.47,138.12,152.07,158.83,203.29。
HRMS(ESI,m/z)calcd.for C32H23ClNO3[M+H]+calc.:504.1361;found:504.1345。
实施例12:
1-(2-甲氧基苯基)-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IL)合成
空气下,向10毫升封管中,加入2-甲氧基苯胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应3小时,然后冷却至室温,得到目标产物式(IL),黄色液体,分离收率75%。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.52(s,3H),3.58(d,J=14.0Hz,1H),3.66(d,J=13.6Hz,1H),5.07(s,1H),6.55(dd,J1=6.8Hz,J2=1.2Hz,1H),6.83(s,1H),6.86-6.89(m,2H),7.05-7.12(m,4H),7.21-7.31(m,8H),7.38(dd,J1=6.6Hz,J2=1.2Hz,1H),7.59(td,J1=6.4Hz,J2=1.6,1H);13C NMR(CDCl3)δ:40.45,55.66,62.59,108.00,110.01,112.47,114.28,117.68,120.09,121.36,123.51,125.34,127.17,127.37,128.13,128.64,128.78,128.80,128.86,130.39,131.81,132.90,135.87,137.75,137.91,152.01,155.59,159.16,203.11。
HRMS(ESI,m/z)calcd.for C33H26NO4[M+H]+calc.:500.1856;found:500.1845。
实施例13:
1-(1-萘基)-2-(3,3-二苯基-2-丙酮基)香豆素并[4,3-b]吡咯(IM)合成
空气下,向10毫升封管中,加入1-萘胺基香豆素0.3mmol、呋喃醇0.45mmol、1,2-二氯乙烷3mL、三氯化铝0.09mmol。在80℃反应5小时,然后冷却至室温,得到目标产物式(IM),黄色液体,分离收率75%。
产物核磁数据:1H NMR(CDCl3,400MHz):δ3.39(d,J=17.6Hz,1H),3.78(d,J=17.6Hz,1H),4.84(s,1H),6.14(dd,J1=8.0Hz,J2=1.6Hz,1H),6.64(t,J=7.6Hz,1H),6.90-6.94(m,5H),7.05(d,J=8.4Hz,1H),7.15-7.22(m,7H),7.34-7.40(m,2H),7.47(dd,J1=7.2Hz,J2=1.2Hz,1H),7.52-7.57(m,2H),8.02(d,J=8.0Hz,1H),8.11(d,J=8.0,1H);13C NMR(CDCl3)δ:40.16,63.19,108.43,110.15,113.78,117.65,120.30,122.10,123.53,125.57,127.25,127.31,127.46,128.22,128.45,128.47,128.64,128.69,130.56,130.70,133.19,133.50,134.25,136.21,137.48,137.55,152.04,159.09,203.16。
HRMS(ESI,m/z)calcd.for C36H26NO3[M+H]+calc.:520.1907;found:520.1890。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (10)
3.根据权利要求2所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,R1为甲基、氯、甲氧基;R2为4-氯苯基、4-甲基苯基、4-酯基苯基、4-氟苯基、4-甲氧基苯基、2-甲氧基苯基、3-甲氧基苯基、1-萘基、正丁基、环戊基;R3为苯基、4-氯苯基、4-甲氧基苯基、正丁基;R4为苯基、4-氯苯基、4-甲氧基苯基、正丁基。
4.根据权利要求2所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,所述催化剂选自ZnCl2、Zn(OTf)2、BiCl3、AlCl3和TFA中的一种或多种。
5.根据权利要求2所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,所述有机溶剂选自1,2-二氯乙烷、乙腈、甲苯和氯仿中的一种或多种。
6.根据权利要求2所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,所述4-氨基香豆素类化合物:呋喃醇类化合物:催化剂的摩尔比为1:(1-2):(0.1-0.5)。
7.根据权利要求2所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,所述反应的温度为50-120℃。
8.根据权利要求2所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,所述反应的时间为1-20h。
9.根据权利要求8所述的一种香豆素并[4,3-b]吡咯类衍生物的合成方法,其特征在于,所述反应的时间为2-5h。
10.如权利要求1所述的香豆素并[4,3-b]吡咯类衍生物在制备抗菌、抗肿瘤、抗氧化、抗HIV或抗凝血药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111019558.0A CN113698412A (zh) | 2021-09-01 | 2021-09-01 | 一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111019558.0A CN113698412A (zh) | 2021-09-01 | 2021-09-01 | 一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113698412A true CN113698412A (zh) | 2021-11-26 |
Family
ID=78658679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111019558.0A Pending CN113698412A (zh) | 2021-09-01 | 2021-09-01 | 一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113698412A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109415373A (zh) * | 2016-06-08 | 2019-03-01 | 方济各安吉利克化学联合股份有限公司 | 新的抗菌化合物 |
-
2021
- 2021-09-01 CN CN202111019558.0A patent/CN113698412A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109415373A (zh) * | 2016-06-08 | 2019-03-01 | 方济各安吉利克化学联合股份有限公司 | 新的抗菌化合物 |
Non-Patent Citations (5)
Title |
---|
DAVID LEBOEUF等: "Harnessing the Lewis Acidity of HFIP through its Cooperation with a Calcium(II) Salt: Application to the Aza-Piancatelli Reaction", 《CHEM. EUR. J.》, vol. 22, 30 September 2016 (2016-09-30), pages 16165 - 16171, XP055804338, DOI: 10.1002/chem.201603592 * |
MARIA J. MATOS等: "Coumarin-Rasagiline Hybrids as Potent and Selective hMAO-B Inhibitors, Antioxidants, and Neuroprotective Agents", 《CHEMMEDCHEM》, vol. 15, no. 6, 27 February 2020 (2020-02-27), pages 532 - 538 * |
VITTORIA COLOTTA等: "Tricyclic heteroaromatic systems. Synthesis of 1,3 and 1,2 disubstituted[1]benzopyrano[4,3-b]pyrrol-4-ones and structure-activity relationships as benzodiazepine receptor ligands", 《FARMACO》, vol. 46, no. 10, 31 December 1991 (1991-12-31), pages 1139 - 1154 * |
YINGCHE CHEN等: "Coumarin-Based Fluorogenic Probes for No-Wash Protein Labeling", 《ANGEW. CHEM. INT. ED.》, vol. 53, 14 October 2014 (2014-10-14), pages 13785 - 13788 * |
杨晓峰: "多组分反应构建吡咯香豆素衍生物及广谱杀菌剂啶氧菌酯的合成研究", 《中国博士学位论文全文数据库工程科技I辑B016-213》, 31 January 2019 (2019-01-31), pages 60 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karami et al. | ZrOCl2. 8H2O/SiO2: An efficient and recyclable catalyst for the preparation of coumarin derivatives by Pechmann condensation reaction | |
Hou et al. | An efficient and convenient protocol for the synthesis of diaminotriarylmethanes | |
CN110790752B (zh) | 一种(异)喹啉和喹喔啉取代的黄酮及喹诺酮衍生物的合成方法 | |
CN108947945B (zh) | 一种1,3-二氢异苯并呋喃衍生物及其合成方法和应用 | |
CN104177241A (zh) | 一种炔基二酮类化合物及其合成方法 | |
Chacko et al. | Synthesis of aminomethylphenol derivatives via magnetic nano Fe _ 3 O _ 4 Fe 3 O 4 catalyzed one pot Petasis borono-Mannich reaction | |
CN111777564B (zh) | 一种在水相中光催化醇氧化合成喹唑啉酮化合物的方法 | |
CN106380440B (zh) | 一种茚酮并吡咯类衍生物及其合成方法和应用 | |
CN113698412A (zh) | 一种香豆素并[4,3-b]吡咯类衍生物及其合成方法和应用 | |
CN110256451B (zh) | 一种苯并呋喃并[2,3-b]喹啉衍生物的合成方法 | |
CN112851652B (zh) | 一种2-(取代氧杂蒽基)苯并呋喃类化合物的催化氧化合成方法 | |
CN111875549B (zh) | 一种在水相中光催化合成喹唑啉酮化合物的方法 | |
CN108892604A (zh) | 一种制备卤代苯并[b]芴酮系列化合物的方法 | |
CN110698426B (zh) | 叔丁醇钾高效催化制备1,3-苯并噻唑衍生物的方法 | |
CN111087338B (zh) | 一种磺酰胺基取代的二氢吡咯酮类衍生物及其制备方法 | |
CN114349759A (zh) | 一种稠环3,3’-联吲哚衍生物及其合成方法 | |
CN107216331B (zh) | 一种四氢萘啶并四氢喹唑啉衍生物及其合成方法和应用 | |
CN115353514B (zh) | 氟代吡啶并嘧啶酮类化合物及其合成方法 | |
CN105622537A (zh) | 一种3,4,5-三取代异恶唑类化合物的合成方法 | |
CN108299303A (zh) | 一种四芳基吡唑类化合物的合成新方法 | |
CN113200980B (zh) | 一种银催化合成中氮茚类化合物的方法 | |
KR101638331B1 (ko) | 호기성 산화법을 이용한 벤즈이미다졸의 합성방법 | |
CN115197135B (zh) | 一种锌催化制备多取代喹啉化合物的方法 | |
CN109678776B (zh) | 3-芳基琥珀酰亚胺类化合物的制备方法 | |
CN113582929B (zh) | 一种2,5-二取代咪唑类化合物的合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211126 |